title: Efficacy of an inactivated FeLV vaccine compared to a recombinant FeLV vaccine in minimum age cats following virulent FeLV challenge.
abstract: The aim of the study was to determine the efficacy of an inactivated feline leukemia virus (FeLV) vaccine (Versifel(®) FeLV, Zoetis.) compared to a recombinant FeLV vaccine (Purevax(®) FeLV, Merial Animal Health) in young cats, exposed under laboratory conditions to a highly virulent challenge model. The study was designed to be consistent with the general immunogenicity requirements of the European Pharmacopoeia 6.0 Monograph 01/2008:1321-Feline Leukaemia Vaccine (Inactivated) with the exception that commercial-strength vaccines were assessed. Fifty seronegative cats (8-9 weeks old) were vaccinated subcutaneously on two occasions, three weeks apart, with either placebo (treatment group T01), Versifel FeLV Vaccine (treatment group T02), or Purevax FeLV Vaccine (treatment group T03) according to the manufacturer's directions. Cats were challenged three weeks after the second vaccination with a virulent FeLV isolate (61E strain). Persistent FeLV antigenemia was determined from 3 to 15 weeks postchallenge. Bone marrow samples were tested for the presence of FeLV proviral DNA to determine FeLV latent infection. At week 15 after challenge with the virulent FeLV 61E strain, the Versifel FeLV Vaccine conferred 89.5% protection against FeLV persistent antigenemia and 94.7% protection against FeLV proviral DNA integration in bone marrow cells. In comparison, the Purevax FeLV Vaccine conferred 20% protection against FeLV persistent antigenemia and 35% protection against FeLV proviral DNA integration in bone marrow cells following challenge. The data from this study show that the Versifel FeLV Vaccine was efficacious in preventing both FeLV persistent p27 antigenemia and FeLV proviral DNA integration in bone marrow cells of cats challenged with this particular challenge model under laboratory conditions and provided better protection than Purevax FeLV in this experimental challenge model with highly virulent FeLV.
authors.affiliation: Zoetis, 20 Mercuriusstraat, 1930 Zaventem, Belgium. Electronic address: kristin.stuke@zoetis.com.
authors.forename: Kristin
authors.initials: K
authors.lastname: Stuke
authors.affiliation: Zoetis, 333 Portage Street, Kalamazoo, MI 49007, USA.
authors.forename: Vickie
authors.initials: V
authors.lastname: King
authors.affiliation: Zoetis, 333 Portage Street, Kalamazoo, MI 49007, USA.
authors.forename: Kendra
authors.initials: K
authors.lastname: Southwick
authors.affiliation: Zoetis, 333 Portage Street, Kalamazoo, MI 49007, USA.
authors.forename: Mira I
authors.initials: MI
authors.lastname: Stoeva
authors.affiliation: Zoetis, 20 Mercuriusstraat, 1930 Zaventem, Belgium.
authors.forename: Anne
authors.initials: A
authors.lastname: Thomas
authors.affiliation: Zoetis, 333 Portage Street, Kalamazoo, MI 49007, USA.
authors.forename: M Teresa C
authors.initials: MT
authors.lastname: Winkler
mesh_terms: D000818:Animals; D000956:Antigens, Viral / Q000097:blood*; D001854:Bone Marrow Cells / Q000821:virology; D002415:Cats; D004279:DNA, Viral / Q000302:isolation & purification; D015683:Gene Products, gag / Q000097:blood*; D005256:Leukemia Virus, Feline; D016582:Leukemia, Feline / Q000517:prevention & control*; D011897:Random Allocation; D015682:Retroviridae Proteins, Oncogenic / Q000008:administration & dosage*; D014611:Vaccination / Q000662:veterinary*; D015164:Vaccines, Inactivated / Q000008:administration & dosage; D014614:Vaccines, Synthetic / Q000008:administration & dosage; D014765:Viral Vaccines / Q000008:administration & dosage*
chemical_list: D000956:Antigens, Viral; D004279:DNA, Viral; D015683:Gene Products, gag; D015682:Retroviridae Proteins, Oncogenic; D015164:Vaccines, Inactivated; D014614:Vaccines, Synthetic; D014765:Viral Vaccines; C117471:feline leukemia virus protein p27; C045569:feline leukemia virus vaccine
keywords: FeLV vaccine; Feline Leukemia Virus; latent infection; persistent antigenemia